Advertisement

Journal of Neuro-Oncology

, Volume 33, Issue 1–2, pp 59–70 | Cite as

Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine

  • Weilian Yang
  • Rolf F. Barth
  • Joan H. Rotaru
  • Melvin L. Moeschberger
  • Darrel D. Joel
  • Marta M. Nawrocky
  • Joseph H. Goodman
Article

Abstract

Boronophenylalanine (BPA) has been used for boron neutron capture therapy (BNCT) of brain tumors in both experimental animals and humans. The purpose of the present study was to determine if the efficacy of BNCT could be enhanced by means of intracarotid (i.c.) injection of BPA with or without blood-brain barrier disruption (BBB-D) and neutron irradiation using a rat brain tumor model. For biodistribution studies, F98 glioma cells were implanted stereotactically into the brains of Fischer rats, and12 days later BBB-D was carried out by i.c. infusion of 25% mannitol (1.373 mOsmol/ml), followed immediately by i.c. administration of 300, 500 or 800 mg of BPA/kg body weight (b.w.). At the 500 mg dose a fourfold increase in tumor boron concentration (94.5 μg/g) was seen at 2.5 hours after BBB-D, compared to 20.8 μg/g in i.v. injected animals. The best composite tumor to normal tissue ratios were observed at 2.5 hours after BBB-D, at which time the tumor: blood (T: Bl) ratio was10.9, and the tumor: brain (T: Br) ratio was 7.5, compared to 3.2 and 5.0 respectively for i.v. injected rats. In contrast, animals that had received i.c. BPA without BBB-D had T: Bl and T: Br ratios of 8.5 and 5.9, respectively, and the tumor boron concentration was 42.7μg/g. For therapy experiments, initiated 14 days after intracerebral implantation of F98 glioma cells, 500 mg/kg b.w. of BPA were administered i.v. or i.c. with or without BBB-D, and the animals were irradiated 2.5 hourslater at the Brookhaven Medical Research Reactor with a collimated beam of thermal neutrons delivered to the head. The mean survival time for untreated control rats was 24 ± 3 days, 30 ± 2 days for irradiated controls, 37 ± 3 days for those receiving i.v. BPA, 52 ± 15 days for rats receiving i.c. BPA without BBB-D, and 95 ± 95 days for BBB-D followed by i.c. BPA and BNCT. The latter group had a 246% increase in life span (ILS) compared to untreated controls and a 124% ILS compared to that of i.v. injected animals. These survival data are the best ever obtained with the F98 glioma model and suggest that i.c. administration of BPA with or without BBB-D may be useful as a means to increase the efficacy of BNCT.

boron neutron capture therapy osmotic blood-brain barrier disruption boronophenylalanine glioma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kornblith PL, Walker M: Chemotherapy for malignant glioma. J Neurosurg 66: 1–17, 1988Google Scholar
  2. 2.
    Laws ER, Thapar K: Brain tumor. CA Cancer J Clin 43: 263–271, 1993Google Scholar
  3. 3.
    Walsh ARW, Darling JL, Thomas DGT: Cerebral gliomas. In: Kennard C (ed) Recent Advances in Clinical Neurology. Churchill Livingston, Edinburgh 241–268, 1990Google Scholar
  4. 4.
    Hatanaka H: Boron-neutron capture therapy for tumors. In: Karim ABMF, Laws ER Jr (eds) Glioma, Principles and Practice in Neuro-Oncology. Springer-Verlag, Berlin 233–249, 1991Google Scholar
  5. 5.
    Bergland R, Elowitz E, Coderre JA, Joel D, Chadha M: A phase I trial of intravenous boronphenylalanine-fructose complex in patients with glioblastoma multiforme. In: Mishima Y (ed) Cancer Neutron Capture Therapy. Plenum Press, New York, 739–746, 1996Google Scholar
  6. 6.
    Barth RF, Soloway AH, Fairchild RG, Brugger RM: Boron neutron capture therapy of brain tumors: past history, current status and future potential. Cancer Invest 14: 534–550, 1996Google Scholar
  7. 7.
    Hawthorne MF: The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Eng 32: 950–984, 1993Google Scholar
  8. 8.
    Hatanaka H, Nakagawa Y: Clinical results of long-survival brain tumor patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28: 1061–1066, 1994Google Scholar
  9. 9.
    Oda Y, Takagaki M, Zhang ZH, Kikuchi H, Kobayashi I, Kanda K: Clinical experience with BNCT for malignant brain tumors. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York, 689–693, 1993Google Scholar
  10. 10.
    Greig NH: Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA (ed) Implications of the Blood-Brain Barrier and its Manipulation. Plenum Press, New York 311–357, 1994Google Scholar
  11. 11.
    Salcman M, Broadwell RD: The blood-brain barrier. In: Salcman M (ed) Neurobiology of Brain Tumors. Williams & Wilkins, Baltimore 229–249, 1991Google Scholar
  12. 12.
    Bullard DE, Bourdon M, Bigner DD: Comparison of various method for delivering radiolabeled monoclonal antibody to normal rat brain. J Neurosurg 61: 901–911, 1984Google Scholar
  13. 13.
    Neuwelt EA, Barnett PA, Hellström KE, Hellström I, MeCormick CI, Ramsey FL: Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med 35: 1831–1841, 1994Google Scholar
  14. 14.
    Neuwelt EA, Barnett PA: Blood-brain barrier disruption in the treatment of brain tumor: animal studies. In: Neuwelt EA (ed) Implications of the Blood-brain Barrier and its Manipulation: Clinical Implication, Vol. 2. Plenum Press, New York 107–194, 1989Google Scholar
  15. 15.
    Neuwelt EA, Frenkel EP: The challenge of the blood-brain barrier. In: Neuwelt EA (ed) Implications of the Blood-brain Barrier and its Manipulation. Plenum Press, New York 1–24, 1989Google Scholar
  16. 16.
    Dahlborg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel R. Neuwelt EA: Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer Sc Am 2: 166–174, 1996Google Scholar
  17. 17.
    Neuwelt EA, Howeison J, Frenkel EP, Specht HD, Weigel R, Buchan C, Hill SA: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement of blood-brain barrier modification in glioblastoma. Neurosurgery 19: 573–583, 1986Google Scholar
  18. 18.
    Williams PC, Hener WD, Roman-Goldstein S, Dahlborg SA, Brummet RE, Tableman M, Dana B, Neuwelt EA: Toxicity and efficacy of carboplatin and etoposide in conjunction with blood-brain tumor barrier modification in the treatment of intracranial neoplasms. Neurosurgery 37: 17–28, 1995Google Scholar
  19. 19.
    Mishima Y: Selective thermal neutron capture therapy for malignant melanoma using melanogenesis-seeking 10B compounds: an overview of basic clinical studies. Nucl Sci Appl 4: 349–359, 1991Google Scholar
  20. 20.
    Mishima Y, Honda C, Ichihashi M, Shiono M, Wadabayashi N, Obara H, Hiratsuka J, Fukuda H, Karashima H, Kanda K, Kobayashi T, Yoshino K: Selective melanoma thermal neutron capture therapy for lymph node metastases. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York 705–710, 1993Google Scholar
  21. 21.
    Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Liu HB: Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex. Int J Radiat Oncol Biol Phys 30: 643–652, 1994Google Scholar
  22. 22.
    Saris SC, Solares GR, Wazer DE, Cano G, Kerley SE, Joyce MA, Adelman LS, Harling OK, Madoc JH, Zamenhof RG: Boron neutron capture therapy for murine malignant gliomas. Cancer Res 52: 4672–4677, 1992Google Scholar
  23. 23.
    Matalka KZ, Bailey MQ, Barth RF, Staubus AE, Moeschberger ML, Coderre AJ: Boron neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent. Radiat Res 137: 44–51, 1994Google Scholar
  24. 24.
    Barth RF, Matalka KZ, Bailey MQ, Staubus AE, Soloway AH, Moeschberger ML, Coderre JA, Rofstad EK: A nude rat model for neutron capture therapy of human intracerebral melanoma. Int J Radiat Oncol Biol Phys 28: 1079–1088, 1994Google Scholar
  25. 25.
    Coderre JA, Kalef-Ezra JA, Fairchild RG, Micca PL, Reinstein LE, Glass JD: Boron neutron capture therapy of murine melanoma. Cancer Res 48: 6313–6316, 1988Google Scholar
  26. 26.
    Yang W, Barth R, Carpenter DE, Moeschberger M, Goodman JH: Enhanced delivery of boronophenylalanine by means of intracarotid injection and blood-brain barrier disruption for neutron capture therapy. Neurosurgery 38: 985–992, 1996Google Scholar
  27. 27.
    Gabel D: Radiobiological considerations concerning the development of compounds for boron neutron capture therapy. Strahlentherapie 169: 65–70, 1993Google Scholar
  28. 28.
    Ko L, Koestner A, Wechsler W: Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol 51: 23–31, 1980Google Scholar
  29. 29.
    Clendenon NR, Barth RF, Gordon WA, Goodman JH, Alam F, Staubus AE, Boesel CP, Yates AJ, Moeschberger ML, Fairchild RG, Kalef-Ezra JA: Boron neutron capture therapy of a rat glioma. Neurosurgery 26: 47–55, 1990Google Scholar
  30. 30.
    Bullard DE, Saris SC, Bigner DD: Carotid artery injections in 40-to 90-g Fischer rats: technical note and evaluation of blood flow by various injection techniques. Neurosurgery 14: 406–411, 1984Google Scholar
  31. 31.
    Schuster JM, Friedman HS, Archer GE, Fuchs HE, McLendon RE, Colvin OM, Bigner DD: Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydro-peroxy-cyclpphosphamide. Cancer Res 53: 2338–2343, 1993Google Scholar
  32. 32.
    Yoshino K, Suzuki A, Mori Y, Kanihana H, Honda C, Mishima Y, Kobayashi T, Kanda K: Improvement of solution of p-boronophenylalanine by complex formation with monosaccharides. Strahlentherapie 165: 127–129, 1989Google Scholar
  33. 33.
    Barth RF, Adams DM, Soloway AH, Mechetner EB, Alam F, Anisuzzaman AKM: Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Anal Chem 63: 890–893, 1991Google Scholar
  34. 34.
    Coderre JA, Joel DD, Micca PL, Nawrocky MM, Slatkin DN: Control of intracerebral gliosarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat Res 129: 290–296, 1992Google Scholar
  35. 35.
    Joel DD, Fairchild RG, Laissue JA, Saraf SK, Kalef-Ezra JA, Slatkin DN: Boron neutron capture therapy of intracerebral rat gliosarcoma. Proc Natl Acad Sci USA 87: 9808–9812, 1990Google Scholar
  36. 36.
    Slatkin DN, Kalaf-Ezra JA, Saraf SK, Joel DD: Neutron beam design, development and performance for neutron capture therapy. In: Harling OA, Bernard JA, Zamenhof (eds) Basic Life Science, Vol. 54. Plenum Press, New York 317–320, 1990Google Scholar
  37. 37.
    Gabel D, Fairchild RG, Borner HG, Larsson B: The relative biological effectiveness in V79 Chinese hamster cells of neutron capture reaction in boron and nitrogen. Radiat Res 98: 307–316, 1984Google Scholar
  38. 38.
    Slatkin DN, Stoner RD, Rosendor KM, Kalef-Ezra JA, Laissue JA: Central nervous system radiation syndrome in mice from preferential 10B(n,?)7Li irradiation of the brain vasculature. Proc Natl Acad Sci USA 85: 4020–4024, 1988Google Scholar
  39. 39.
    Fairchild RG, Kalef-Ezra JA, Fiarman S, Wielopolski L, Hanz J, Mussolino S, Wheeler F: Optimization of an epithermal beam for NCT at Brookhaven Medical Research Reactor (BMRR). Strahlenther Onkol 165: 215–217, 1989Google Scholar
  40. 40.
    Barth RF, Yang W, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH, Soloway AH: Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either socium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res 57: 1129–1136, 1997Google Scholar
  41. 41.
    Gahbauer RA, Fairchild RG, Goodman JH, Blue TE: RBE in normal tissue studies. In: Gabel D, Moss R (eds) Boron Neutron Capture Therapy: Toward Clinical Trials of Glioma Treatment. Plenum Press, New York 123–128, 1992Google Scholar
  42. 42.
    Kaneko S, Allen NJ, Clendenon NR, Kartha M: Treatment schedule of combination using radiation and ACNU in the experimental brain tumors. Neurol Med Chir 23: 849–855, 1983Google Scholar
  43. 43.
    Kaneko S, Clendenon NR, Kartha M: Experimental study in a rat brain tumor by combined treatment with cis-DDP and irradiation. Neurol Med Chir (Tokyo) 23: 917–923, 1983Google Scholar
  44. 44.
    Tzeng JJ, Barth RF, Orosz CG, James SM: Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumor. Cancer Res 51: 2373–2378, 1991Google Scholar
  45. 45.
    Pardridge WM: Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Delivery Rev 15: 5–36, 1995Google Scholar
  46. 46.
    Bullard DE, Bigner SH, Bigner DD: Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 45: 5240–5245, 1985Google Scholar
  47. 47.
    Fenstermacher CD: Intra-arterial infusion of drugs and hyperosmotic solutions as a way of enhancing CNS chemotherapy. Cancer Treat Rep 65: 27–37, 1981Google Scholar
  48. 48.
    Levin VA, Kabra PM, Freeman MA: Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 48: 587–593, 1978Google Scholar
  49. 49.
    Fenstermacher CD, Cowles AL: Theoretic limitation of intracarotid infusion in brain tumor chemotherapy. Cancer Treat Rep 61: 519–526, 1977Google Scholar
  50. 50.
    Greenberg HS, Ensminger WD, Chandler WF, Layton PO, Junck L, Knake J, Vine AK: Intra-artery BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg 61: 423–429, 1984Google Scholar
  51. 51.
    Newton HB, Page MA, Junck L, Greenberg HS: Intra-arterial cisplatin for the treatment of malignant glioma. J Neurosurg 7: 39–45, 1989Google Scholar
  52. 52.
    Theron J, Villemure JD, Worthington C, Tyler JL: Superselective intracerebral chemotherapy of malignant tumors with BCNU. Neuroradiology 28: 118–125, 1986Google Scholar
  53. 53.
    Saris SC, Blasberg RG, Carson RE, DeVroom HL, Lutz R, Dedrick RL, Pettigrew K, Chang R, Doppman J, Wright DC, Herscovitch P, Oldfield EH: Intravascular streaming during carotid artery infusions. J Neurosurg 74: 763–772, 1991Google Scholar
  54. 54.
    Lahann T, Sills C, Hematillake G, Dymock T, Daniell G: Cardiovascular toxicities associated with intravenous administration of p-boronophenylalanine formulations. In: Soloway AH, Barth RF, Carpenter DE (eds) Advances in Neutron Capture Therapy. Plenum Press, New York 513–517, 1993Google Scholar
  55. 55.
    Jain RK: Barriers to drug delivery in solid tumors. Scientific American 271: 58–65, 1994Google Scholar
  56. 56.
    Groothuis DR, Fischer JM, Vick NA, Bigner DD: Comparative permeability of different glioma models to horseradish peroxidase. Cancer Treat Rep 65: 13–18, 1981Google Scholar
  57. 57.
    Gummerlock MK, Neuwelt EA: Chemotherapy of brain tumors: Innovative approaches. In: Morantz RG, Walsh JW, Dekker M (eds) Handbook of Brain Tumors. Plenum Press, New York 763–778, 1993Google Scholar
  58. 58.
    Miyagami M, Tsubokawa T, Tazoe M, Kagawa Y: Intra-arterial ACNU chemotherapy employing 20% mannitol osmotic blood-brain barrier disruption for malignant brain tumor. Neurol Med Chir (Tokyo) 30: 582–590, 1990Google Scholar
  59. 59.
    Yang W, Barth RF, Rotaru J, Carpenter DE, Goodman JH: Enhanced survival of F98 glioma bearing rats following neutron capture therapy with either sodium borocaptate or boronophenylalanine and osmotic blood-brain barrier disruption. Anticancer Res 15: 5A: 1658, 1995Google Scholar
  60. 60.
    Yang W, Barth RF, Rotaru JH, Joel DD, Nawrocky MM, Moeschberger ML, Goodman JH, Soloway AF: Beuron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int J Radiation Biol Phys 37: 663–672, 1997Google Scholar
  61. 61.
    Inamura T, Nomura T, Bartus RT, Black KL: Intracarotid infusion of RMP-7, a bradykinin analogue: a method for selective drug delivery to brain tumors. J Neurosurg 81: 752–758, 1994Google Scholar
  62. 62.
    Nomura T, Inamura T, Black KL: Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 659: 62–66, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Weilian Yang
    • 1
  • Rolf F. Barth
    • 1
  • Joan H. Rotaru
    • 1
  • Melvin L. Moeschberger
    • 2
  • Darrel D. Joel
    • 4
  • Marta M. Nawrocky
    • 4
  • Joseph H. Goodman
    • 3
  1. 1.Department of PathologyThe Ohio State UniversityColumbusUSA
  2. 2.Division of Epidemiology and Biometrics/School of Public HealthThe Ohio State UniversityColumbusUSA
  3. 3.Division of NeurosurgeryThe Ohio State UniversityColumbusUSA
  4. 4.Brookhaven National LaboratoryUptonUSA

Personalised recommendations